Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wöhrer, S.
Right arrow Articles by Raderer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wöhrer, S.
Right arrow Articles by Raderer, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1758-1761, 2003
© 2003 European Society for Medical Oncology

Original Paper

Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP)

S. Wöhrer1, J. Drach1, M. Hejna1, W. Scheithauer1, A. Dirisamer2, A. Püspök3, A. Chott4 and M. Raderer1,+

Departments of Internal Medicine I, 1 Divisions of Oncology and 2 Radiology, Internal Medicine IV, 3 Divisions of Gastroenterology and 4 Clinical Pathology, University of Vienna, Vienna, Austria

Received 21 May 2003; revised 11 June 2003; accepted 12 August 2003

Background:

Mucosa-associated lymphoid tissue (MALT) lymphoma is a relatively common type of lymphoma arising in various tissues throughout the human body. Currently, there is no standard chemotherapy for advanced stage MALT lymphoma. This has prompted us to retrospectively analyse our experience with the MCP regimen (mitoxantrone, chlorambucil and prednisone) in patients with MALT lymphoma.

Patients and methods:

Patients with histologically verified MALT lymphoma undergoing chemotherapy with MCP were evaluated retrospectively. The MCP regimen consists of mitoxantrone 8 mg/m2 intravenously on days 1 and 2, chlorambucil 3 x 3 mg/m2 per os (p.o.) on days 1–5 and prednisone 25 mg/m2 p.o. on days 1–5. Information analysed included localisation of the lymphoma, clinical stage, pretreatment, number of chemotherapy cycles administered, toxicity, response to treatment, follow-up time, relapse and survival.

Results:

A total of 15 patients (six females and nine males aged between 34 and 88 years) with histologically ascertained MALT lymphoma undergoing treatment with the MCP regimen were identified from our records. Ten patients had extragastric lymphoma, while five patients suffered from gastric MALT lymphoma. All patients were chemotherapy-naïve, while two had been locally irradiated before application of MCP for recurrent disease. A total of 74 cycles was administered to our patients, with a median number of five cycles per patient. Eight (53%) patients achieved complete remission, six (40%) patients partial response and only one (7%) patient had progressive disease. Subjective tolerance was excellent, and toxicities were mainly haematological, including granulocytopenia World Health Organisation grade 3 and 4 in three patients each. In two patients, this was accompanied by single episodes of uncomplicated herpes simplex infection. At the time of analysis, all patients are still alive. No relapses have occurred after a median follow-up time of 16 (range 12–29) months.

Conclusions:

Our data suggest that MCP is an effective and well-tolerated regimen for treatment of patients with MALT lymphoma irrespective of localisation. Judging from our data, MCP also appears to be a feasible regimen in elderly patients.

Key words: chemotherapy, chlorambucil, MALT lymphoma, mitoxantrone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Wohrer, M. Troch, B. Streubel, M. Hoffmann, L. Mullauer, A. Chott, and M. Raderer
Pathology and clinical course of MALT lymphoma with plasmacytic differentiation
Ann. Onc., December 1, 2007; 18(12): 2020 - 2024.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Herold, A. Haas, S. Srock, S. Neser, K. H. Al-Ali, A. Neubauer, G. Dolken, R. Naumann, W. Knauf, M. Freund, et al.
Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study
J. Clin. Oncol., May 20, 2007; 25(15): 1986 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Raderer, S. Wohrer, R. Bartsch, G. Prager, J. Drach, M. Hejna, A. Gaiger, K. Turetschek, U. Jaeger, B. Streubel, et al.
Phase II Study of Oxaliplatin for Treatment of Patients With Mucosa-Associated Lymphoid Tissue Lymphoma
J. Clin. Oncol., November 20, 2005; 23(33): 8442 - 8446.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Bertoni and E. Zucca
State-of-the-Art Therapeutics: Marginal-Zone Lymphoma
J. Clin. Oncol., September 10, 2005; 23(26): 6415 - 6420.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.